// App-Quantinova.ai

POS0704 (2022) : EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE, WITH 4 OR <4 POOR PROGNOSTIC FACTORS: A POST HOC ANALYSIS OF THE FINCH 1 STUDY

Researchers

Presenter

  • B. Combe

Principal Investigators

  • Y. Tanaka

  • M. H. Buch

  • G. R. Burmester

  • B. Bartok

  • A. Pechonkina

  • L. Han

  • K. Emoto

  • S. Kano

  • T. Hendrikx

  • D. Aletaha

Medical Centers

  • The University of Montpellier, Department of Rheumatology, CHU Montpellier, Montpellier, France

  • University of Occupational and Environmental Health, Japan, The second department on internal medicine, Kitakyusyu, Japan

  • University of Manchester, Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Medicine & Health, Manchester, United Kingdom

  • Charite University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany.

  • Gilead Sciences, Inc., Clinical Development, Foster City, United States of America

  • Gilead Sciences, Inc., Biostatistics, Foster City, United States of America

  • Gilead Sciences K.K., Medical Affairs, Tokyo, Japan

  • Galapagos NV, Medical Affairs, Leiden, Netherlands

  • Medical University of Vienna, Division of Cardiology, Vienna, Austria

Locations

  • France

  • Japan

  • United Kingdom

  • Germany

  • United States

  • Netherlands

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Complement Factor B

  • High sensitivity C-reactive protein

Drug/Treatment

  • Methotrexate

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • N/A

Study Id's

  • NCT02889796

Sponsors

  • Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved